Fusion Pharmaceuticals Announces Incentive Grants Under Nasdaq Listing Rule 5635(c)(4)

HAMILTON, ON and BOSTON, March 9, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Compensation Committee of the Company’s Board of Directors has granted stock option awards a total of 101,200 shares of its common stock to two employees outside of Merger’s 2020 Stock Option and Incentive Plan . The stock options were granted as an incentive to the person becoming an employee of Fusion pursuant to Nasdaq listing rule 5635(c)(4).

Options have an exercise price of $7.00 per share, which is equal to the closing price of the common shares of Merger on March 7, 2022. Each option has a term of ten years and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the grant date, then in equal installments for 36 months thereafter, subject to the employee’s continued presence. with Merger until the applicable vesting dates.

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion links alpha particle-emitting isotopes to various targeting molecules to selectively deliver alpha-emitting payloads to tumors. Fusion’s lead program, FPI-1434 targeting the insulin-like growth factor receptor 1, is currently in Phase 1 clinical testing. The pipeline includes FPI-1966, targeting fibroblast growth factor receptor 3 (FGFR3), moving to a Phase 1 study following recent Investigational New Drug (IND) authorization; and FPI-2059, a small molecule targeting neurotensin 1 receptor (NTSR1). In addition to a robust proprietary pipeline, Fusion is collaborating with AstraZeneca to co-develop novel targeted alpha therapies (TATs) and combination programs between Fusion’s TATs and DNA damage repair inhibitors (DDRis) d ‘AstraZeneca and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck’s KEYTRUDA® (pembrolizumab) in patients with IGF-1R-expressing solid tumors. Merger and Hamilton, Ont.-based McMaster University are currently constructing a Good Manufacturing Practices (GMP) radiopharmaceutical manufacturing facility designed to support the manufacturing of the company’s growing TAT pipeline.

For more information: Amanda Craysenior director of investor relations and corporate communications, 617-967-0207, [email protected]

SOURCE Fusion Pharmaceuticals Inc.